NCT01792479View on ClinicalTrials.gov

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

BIND-014

Trial Locations (17)

15232

Investigative Site #05, Pittsburgh

19124

Investigative Site #11, Philadelphia

30265

Investigative Site #08, Newnan

33905

Investigative Site #02, Fort Meyers

37203

Investigative Site #01, Nashville

43221

Investigative Site #03, Columbus

60099

Investigative Site #07, Zion

74133

Investigative Site #09, Tulsa

85338

Investigative Site #10, Goodyear

90048

Investigative Site #04, Los Angeles

97758

Investigative Site #13, Saint-Petersberg

115478

Investigative Site #12, Moscow

198255

Investigative Site #14, Saint-Petersberg

450054

Investigative Site #16, Ufa

454087

Investigative Site #15, Chelyabinsk

Unknown

Site #17, Krasnodar

Site # 18, Saint Petersburg

Sponsors

Lead Sponsor

BIND Therapeutics
All Listed Sponsors
lead

BIND Therapeutics

INDUSTRY

NCT01792479 - A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter